Warning: The NCBI web site requires JavaScript to function. more...
Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.
Dunfee RL, Thomas ER, Gabuzda D.
Retrovirology. 2009 Jul 20;6:69.
Related citations
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D.
Virology. 2007 Oct 10;367(1):222-34. Epub 2007 Jun 27.
Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.
J Gen Virol. 2010 May;91(Pt 5):1354-64. Epub 2010 Jan 6.
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S, Flora MN, Quinnan GV Jr.
J Virol. 2002 Jan;76(2):644-55.
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ.
J Virol. 2009 May;83(10):5077-86. Epub 2009 Mar 4.
A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.
Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR.
J Virol. 2011 Mar;85(5):2397-405. Epub 2010 Dec 15.
The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F, Querido B, Nimmagadda M, Cocklin S, Navas-Martín S, Martín-García J.
Retrovirology. 2008 Oct 6;5:89.
A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A, Honnen WJ, Racho ME, Tilley SA.
AIDS Res Hum Retroviruses. 1993 Oct;9(10):985-96.
Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C.
Virology. 1997 Mar 17;229(2):360-9.
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS.
J Virol. 2004 Sep;78(17):9233-42.
Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.
J Virol. 2010 May;84(9):4311-20. Epub 2010 Feb 17.
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV Jr, Parren PW, Burton DR.
J Virol. 2003 Jun;77(12):6965-78.
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.
Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, Bell JE, Wolinsky SM, Gabuzda D.
Virology. 2007 Mar 30;360(1):105-19. Epub 2006 Nov 7.
Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages.
Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR.
J Virol. 2004 Jul;78(13):6915-26. Erratum in: J Virol. 2005 Mar;79(5):3227.
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR.
J Virol. 1994 Aug;68(8):4821-8.
Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.
Richards KH, Aasa-Chapman MM, McKnight A, Clapham PR.
Retrovirology. 2010 May 27;7:48.
Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham PR.
Retrovirology. 2008 Jan 18;5:5.
Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A, Blanco J, Krust B, Franco R, Hovanessian AG.
J Virol. 1997 Nov;71(11):8289-98.
Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues.
Peters PJ, Dueñas-Decamp MJ, Sullivan WM, Clapham PR.
J Neuroimmune Pharmacol. 2007 Mar;2(1):32-41. Epub 2006 Nov 7. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on